In this task, you are given a multiple-choice question about healthcare. Answer the question based on your information and classify your answers into '1', '2', '3', and '4'.

Question: Indicate in what clinical situation would NOT indicate beginning interferon beta in a patient diagnosed with multiple sclerosis: 
 Options:  <1> Multiple recurring outbreaks. <2> Bad response to corticosteroids in outbreaks. <3> Having suffered a single outbreak of the disease with sequelae. <4> Be over 50 years old <5> A progressive primary clinical form.
5

Question: Point out the correct answer regarding the regulation of hematopoiesis: 
 Options:  <1> Altitude inhibits hematopoiesis. <2> Erythropoietin inhibits hematopoiesis. <3> Hypoxia stimulates the production of erythropoietin. <4> Erythropoietin is synthesized in the liver. <5> Erythropoietin does not influence the production of red blood cells.
3

Question: In a clinical trial, the non-inferiority of the HDP-MDI inhaler (experimental) was evaluated against the FDC-ELIPTUS inhaler (control). The lower clinically relevant limit was set at -50 ml in the forced expiratory volume in the first second (FEV1). The results showed an absolute difference in FEV1 between treatments of +8 mL in favor of the HDP-MDI inhaler (95% confidence interval: -59 ml to +67 ml). Point out the CORRECT answer: 
 Options:  <1> The new HDP-MDI inhaler is superior to the control inhaler. <2> The FDC-ELIPTUS inhaler is non-inferior to the experimental inhaler. <3> The study is not conclusive. <4> Both inhalers are equivalent. <5> The HDP-MDI inhaler is non-inferior to the control inhaler.

3